In short
Clinical trials are investigating Astegolimab in people with chronic obstructive pulmonary disease (COPD). These studies look at whether it can help reduce flare-ups and whether it is safe and effective in the target patient groups.
Key points
- Clinical trials of Astegolimab are focused on chronic obstructive pulmonary disease (COPD). The main completed study was a Phase 3 trial in 1,198 patients and compared Astegolimab with placebo. Its main goal was to measure the yearly rate of moderate and severe COPD flare-ups over 52 weeks. Another interventional trial with 556 participants is listed as authorised, but the source does not give its condition or outcomes. Overall, the trial data show research aimed at understanding how well Astegolimab works in COPD and how safe it is in larger patient groups.
Trial overview
The trial data show two interventional studies of Astegolimab, meaning the researchers gave a treatment and watched what happened in patients. One study is a completed Phase 3 trial in people with chronic obstructive pulmonary disease (COPD). The other study is listed as authorised, but the source does not give its condition, phase, or outcome measure.
Phase 3 COPD study
The main study is titled “A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease.” It was a Phase 3 trial, which is a late-stage study done in a larger group of patients to see how well a treatment works and to gather more safety information. The trial was completed and enrolled 1,198 participants.
This study compared Astegolimab with placebo. A placebo is a look-alike treatment with no active study drug, used so researchers can compare results in a fair way. The brief summary says the study aimed to evaluate the efficacy of Astegolimab compared with placebo over a 52-week treatment period.
Other authorised interventional study
Another trial record for Astegolimab is listed as authorised and interventional, with 556 participants. The source does not provide the condition being studied, the phase, the treatment details, or the endpoint for this record. Because of that, only the basic trial status and enrollment can be reported from the available data.
Who the trials involve and how they are designed
The completed Phase 3 study focused on patients with COPD. COPD is a long-term lung disease that can cause breathing problems and flare-ups, which are times when symptoms get worse. The study was designed as a comparison between Astegolimab and placebo, which helps show whether the study treatment leads to better results than no active treatment.
The authorised study is also interventional, so it involved giving a study treatment or study plan directly to participants. However, the available source does not say which patients were eligible or what medical condition was being studied.
What the trials measure
The main endpoint, or main result being measured, in the COPD study was the annualized rate of moderate and severe COPD exacerbations over 52 weeks. An endpoint is the main question a trial tries to answer. In this case, the researchers wanted to know how often patients had flare-ups during the treatment period.
Moderate and severe exacerbations are important because they show how often COPD gets worse and how serious those worsening episodes are. The study summary specifically says the goal was to evaluate efficacy, meaning how well the treatment works, by using this flare-up rate as the main measure.
Why these trials matter for patients
These studies are important because they focus on a common and serious lung disease where flare-ups can affect daily life and overall health. A completed Phase 3 trial with more than 1,000 participants gives useful information about Astegolimab in a larger COPD group. The authorised trial with 556 participants shows that research on Astegolimab is also continuing in another interventional setting, even though the source does not give full details.